EDK Editome Disease Knowledgebase

  1. Home
  2. Editing Dependent Virus
  3. Ebola virus

Ebola virus - EBOV

Virus Host Enzyme Edited Genes Phenotype Disease Details
Ebola virus NA NA NA Antiviral Severe hemorrhagic disease
  • Edited Gene Alias: NA
  • Editing Site: NA
  • Editing Type: U-to-C
  • Amino Acid Change: NA
  • Editing Level: Present
  • Molecular Consequence: NA
  • Correlation: Positive
  • Description: Ebola virus infected with non-human primates was divided into 7U and 8U editing status according to the Poly-U site of GP, and the virus with 8U at the Poly-U site showed stronger growth activity compared with the virus with only 7 uridine
  • PMID: 26703716
Ebola virus Guinea pig NA Glycoprotein Contribute to the high pathogenicity Severe hemorrhagic disease
  • Edited Gene Alias: G gene
  • Editing Site: NA
  • Editing Type: NA
  • Amino Acid Change: NA
  • Editing Level: Present
  • Molecular Consequence: Influence viral surface gene expression
  • Correlation: Negative
  • Description: In conclusion, data obtained indicate that downregulation of the level of surface GP expression through a mechanism of GP gene RNA editing plays an important role in the high pathogenicity of EBOV.
  • PMID: 26138826
Ebola virus Guinea pig NA Glycoprotein Leads to the appearance and rapid predominanc Severe hemorrhagic disease
  • Edited Gene Alias: G gene
  • Editing Site: NA
  • Editing Type: NA
  • Amino Acid Change: NA
  • Editing Level: Present
  • Molecular Consequence: NA
  • Correlation: Negative
  • Description: The EBOV/7U phenotype has a selective advantage that is linked to controlled expression of GP and/or expression of secreted sGP, the primary gene product for wild-type EBOV
  • PMID: 21987773
Ebola virus Mice NA Glycoprotein Characterized a new non-structural glycoprote Severe hemorrhagic disease
  • Edited Gene Alias: G gene
  • Editing Site: NA
  • Editing Type: NA
  • Amino Acid Change: NA
  • Editing Level: Present
  • Molecular Consequence: NA
  • Correlation: Negative
  • Description: The researchers have identified and characterized a new EBOV non- structural glycoprotein, which is expressed as a result of transcriptional editing of the GP gene.
  • PMID: 21411529
Ebola virus Human; Monkey NA Glycoprotein Encoded full-length glycoprotein Severe hemorrhagic disease
  • Edited Gene Alias: G gene
  • Editing Site: NA
  • Editing Type: A insertion
  • Amino Acid Change: NA
  • Editing Level: Present
  • Molecular Consequence: NA
  • Correlation: Negative
  • Description: The editing site in the Ebola virus glycoprotein gene is recognized not only by Ebola virus polymerase but also by DNA-dependent RNA polymerases of different origin.
  • PMID: 8553543
Ebola virus Human NA VP30 Produce novel function for this protein Severe hemorrhagic disease
  • Edited Gene Alias: NA
  • Editing Site: NA
  • Editing Type: NA
  • Amino Acid Change: NA
  • Editing Level: Present
  • Molecular Consequence: NA
  • Correlation: NA
  • Description: The EBOV protein VP30 was identified as a trans-acting factor for RNA editing, constituting a novel function for this protein.
  • PMID: 24146620
Ebola virus Human ADAR1 Glycoprotein; MARV-Ang nucleoprotein; MARV-An Produce a new genetic subclass Severe hemorrhagic disease
  • Edited Gene Alias: NA
  • Editing Site: NA
  • Editing Type: A-to-I
  • Amino Acid Change: NA
  • Editing Level: Present
  • Molecular Consequence: NA
  • Correlation: NA
  • Description: These studies identify novel filovirus-host interactions and reveal production of a greater diversity of filoviral gene products than was previously appreciated.
  • PMID: 25370495
Ebola virus Human ADAR1 Glycoprotein Promote virus pathogenicity Severe hemorrhagic disease
  • Edited Gene Alias: NA
  • Editing Site: NA
  • Editing Type: G insertion
  • Amino Acid Change: NA
  • Editing Level: Present
  • Molecular Consequence: NA
  • Correlation: NA
  • Description: Synthesis of Ebola virus (EBOV) surface glycoprotein (GP) is dependent on transcriptional RNA editing. In addition to full length GP messenger RNAs (mRNAs), a shorter RNA is also synthesized, sequence analysis demonstrates that this RNA is a truncated version of the full-length GP mRNA that is polyadenylated at the editing site and thus lacks a stop codon, nonstop GP mRNA was shown to be only slightly less stable than the same mRNA containing a stop codon, the RNA-editing is function to edit GP mRNA for expression of surface GP. The downregulation of surface GP expression is even more dramatic, reinforcing the importance of the GP gene editing site for EBOV replication and pathogenicity. During EBOV infection and transcription of GP, approximately 20% of transcripts are edited, while the other 80% of unedited transcripts possess a premature stop codon. This results in the synthesis of a number of different products including a truncated glycoprotein product (soluble GP - sGP), which is then secreted into the extracellular space.
  • PMID: 25416632;25838269